Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Aquestive Therapeutics ( (AQST) ) is now available.
On October 8, 2025, Aquestive Therapeutics announced the issuance of two new U.S. patents for Anaphylm™, a novel epinephrine prodrug sublingual film, extending its protection until 2037. This development is significant as Anaphylm, if approved by the FDA, will be the first oral medication for severe allergic reactions, providing a needle-free alternative to epinephrine injections, thus potentially impacting the treatment landscape for anaphylaxis.
The most recent analyst rating on (AQST) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
Aquestive Therapeutics’ stock score is primarily impacted by its weak financial performance, characterized by declining revenues and high leverage. While technical analysis shows positive momentum, the valuation remains unattractive due to negative earnings. The earnings call provided some optimism regarding product development, but financial challenges persist.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies. The company specializes in developing orally administered products to deliver complex molecules, offering alternatives to traditional therapies. Aquestive has four commercialized products and collaborates with other pharmaceutical companies using proprietary technologies like PharmFilm®.
Average Trading Volume: 2,312,670
Technical Sentiment Signal: Buy
Current Market Cap: $722.2M
For detailed information about AQST stock, go to TipRanks’ Stock Analysis page.